CAR-T makers converge on UNC Chapel Hill Friday for the North Carolina Biotechnology Center’s 7th cell and gene therapy symposium, five days after Eli Lilly dropped $3.25 billion upfront for Kelonia’s in-vivo CAR-T platform.
The timing isn’t an accident. Kelonia’s pitch is AAV-delivered CAR-T that skips the patient-by-patient ex vivo manufacturing defining every approved cell therapy on the market. That CMC pivot maps directly onto NC Biotech’s agenda: viral safety in AAV manufacturing, automation in CAR-T, machine learning in CRISPR design. The headline panel asks the question the whole field is trying to answer. “Is Automation the Missing Link in CAR-T Therapy Manufacturing?”
It lands in a week where the CAR-T story got heavier. Gilead and Arcus just walked from their TIGIT partnership after a phase 3 futility call, leaving AstraZeneca’s rilvegostomig as the last bispecific standing. That makes CAR-T the cleanest immuno-oncology bet left for anyone with capital. The autoimmune-CAR-T race, now eyeing a first FDA nod, adds a fresh regulatory lane to the same manufacturing bottleneck.
AskBio, Bayer’s Research Triangle AAV subsidiary, is fronting as platinum sponsor. AcroBiosystems is matching. Gold tier runs Cytiva, Millipore Sigma, Kymanox. The crowd skews regulatory affairs and process development. CMC problems don’t get solved at demo days.
Doors at The Friday Conference Center open at 8am. The manufacturing bottleneck is the deal limiter now.